General Pharmacology Practice Questions

Q: Which of the following drugs is NOT used in the management of obesity?

Neuropeptide Y Agonist. **Explanation:** The management of obesity involves drugs that either decrease nutrient absorption, suppress appetite (anorexiants), or increase energy expenditure. **Why Neuropeptide Y (NPY) Agonist is the correct answer:** Neuropeptide Y is one of the most potent **orexigenic** (appetite-stimulating) peptides found in the hypothalamus. It stimulates the Y1 and Y5 receptors to increase food intake and promote fat storage. Therefore, an **agonist** would cause weight gain, not loss. To treat obesity, one would theoretically use an NPY **antagonist**, though none are currently mainstay clinical treatments. **Analysis of Incorrect Options:** * **Orlistat:** A potent, reversible inhibitor of **gastric and pancreatic lipases**. It prevents the dietary breakdown of triglycerides into absorbable free fatty acids, reducing fat absorption by approximately 30%. * **Sibutramine:** A combined norepinephrine and serotonin reuptake inhibitor (SNRI). It acts as an anorexiant by increasing satiety. *Note: It has been withdrawn in many countries due to cardiovascular risks, but remains a classic "textbook" example of an anti-obesity drug.* * **Olestra:** A **non-absorbable fat substitute** used in food preparation. It mimics the texture of fat but cannot be hydrolyzed by digestive enzymes, thus contributing zero calories. **High-Yield Clinical Pearls for NEET-PG:** * **Liraglutide/Semaglutide:** GLP-1 receptor agonists are currently the "gold standard" for pharmacological weight loss. * **Lorcaserin:** A selective 5-HT$_{2C}$ receptor agonist (anorexiant). * **Qsymia:** A fixed-dose combination of Phentermine and Topiramate. * **Side Effect Tip:** Orlistat is notorious for causing **steatorrhea** (oily spotting) and deficiency of fat-soluble vitamins (A, D, E, K).

Q: Which one of the following is a prodrug?

Enalapril. **Explanation:** **Enalapril** is the correct answer because it is a **prodrug**, an inactive compound that must undergo metabolic conversion (usually in the liver) to become its active form, **Enalaprilat**. Most ACE inhibitors are prodrugs designed to improve oral bioavailability; Enalaprilat itself is poorly absorbed from the GI tract and is only available for intravenous use in hypertensive emergencies. **Analysis of Incorrect Options:** * **Dopamine (A):** This is an active catecholamine. While its precursor, **Levodopa**, is a classic prodrug used in Parkinson’s disease, Dopamine itself acts directly on receptors. * **Ampicillin (B):** This is an active beta-lactam antibiotic. However, its ester derivatives like **Pivampicillin** or **Bacampicillin** are prodrugs. * **Prednisolone (D):** This is the active metabolite of the prodrug **Prednisone**. Prednisone must be converted to Prednisolone by the 11-β-hydroxysteroid dehydrogenase enzyme in the liver to exert its effect. **High-Yield Clinical Pearls for NEET-PG:** * **ACE Inhibitor Exception:** All ACE inhibitors are prodrugs **EXCEPT Captopril and Lisinopril**. (Mnemonic: *Lisinopril and Captopril are already active*). * **Active Metabolites:** Always distinguish between a prodrug (inactive) and a drug with active metabolites (e.g., Diazepam is active, but its metabolite Nordiazepam is also active). * **Common Prodrugs to Remember:** Levodopa (to Dopamine), Enalapril (to Enalaprilat), Cyclophosphamide (to Phosphoramide mustard), Clopidogrel (to active thiol metabolite), and Valacyclovir (to Acyclovir).

Q: Which of the following is the exact mechanism of action of Nitric Oxide (NO)?

Increase in cyclic guanosine monophosphate (cGMP). **Explanation:** Nitric Oxide (NO), also known as Endothelium-Derived Relaxing Factor (EDRF), is a potent endogenous vasodilator. Its mechanism of action is a high-yield topic for NEET-PG: 1. **Mechanism of the Correct Answer (B):** Nitric Oxide is a gas that diffuses across cell membranes into vascular smooth muscle cells. Once inside, it binds to and activates the enzyme **soluble Guanylyl Cyclase (sGC)**. This enzyme catalyzes the conversion of Guanosine Triphosphate (GTP) to **cyclic Guanosine Monophosphate (cGMP)**. Increased levels of cGMP activate Protein Kinase G (PKG), which leads to dephosphorylation of myosin light chains and sequestration of intracellular calcium, resulting in smooth muscle relaxation and vasodilation. 2. **Why Incorrect Options are Wrong:** * **Option A:** cAMP is the second messenger for drugs like Beta-2 agonists (Salbutamol) and Prostacyclin ($PGI_2$). While it also causes vasodilation, it is not the pathway for NO. * **Options C & D:** Prostaglandins ($PGE_2$ and $PGD_2$) are lipid mediators derived from arachidonic acid via the cyclooxygenase pathway. While they are involved in inflammation and vasodilation, they are not the mediators of NO action. (Note: $PGD_4$ is not a standard physiological prostaglandin). **Clinical Pearls for NEET-PG:** * **Nitrates (Nitroglycerin):** Act as prodrugs that are metabolized to release NO. * **Sildenafil (Viagra):** Inhibits Phosphodiesterase-5 (PDE-5), the enzyme that breaks down cGMP, thereby prolonging the effects of NO. * **Inhaled NO:** Used clinically in the treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN). * **Precursor:** L-arginine is the amino acid precursor for NO synthesis via the enzyme Nitric Oxide Synthase (NOS).

Q: A 40-year-old female with a history of myasthenia gravis on treatment with azathioprine presents with arthritis involving the knee joint and a serum uric acid of 12 mg%. Which of the following is the best drug for lowering uric acid in this patient?

febuxostat. **Explanation:** The core concept in this question is the **clinically significant drug-drug interaction** between Xanthine Oxidase (XO) inhibitors and 6-mercaptopurine (6-MP). 1. **Why Febuxostat is correct:** The patient is taking **Azathioprine** for myasthenia gravis. Azathioprine is a prodrug that is converted into **6-mercaptopurine (6-MP)**. 6-MP is primarily metabolized and inactivated by the enzyme **Xanthine Oxidase**. * **Allopurinol** is a purine-analog inhibitor of XO. It significantly inhibits the metabolism of 6-MP, leading to toxic levels of the drug, which causes life-threatening bone marrow suppression (pancytopenia). * **Febuxostat** is a non-purine selective inhibitor of XO. While it also inhibits XO, clinical guidelines and pharmacological principles dictate that if an XO inhibitor must be used, allopurinol is strictly contraindicated with azathioprine. However, in the context of this specific MCQ, Febuxostat is the "best" choice because it avoids the hypersensitivity risks of allopurinol, though in practice, both require extreme caution or dose reduction of azathioprine (usually by 75%). 2. **Why other options are incorrect:** * **Allopurinol:** Contraindicated due to the high risk of severe bone marrow toxicity when combined with azathioprine. * **Penicillamine:** This is a chelating agent used in Wilson’s disease and sometimes in rheumatoid arthritis; it has no role in lowering serum uric acid levels. **Clinical Pearls for NEET-PG:** * **High-Yield Interaction:** Always check for Azathioprine or 6-MP before prescribing Allopurinol. * **Alternative:** If a patient on Azathioprine develops gout, **Uricosuric agents** (like Probenecid) are safer alternatives as they do not interfere with 6-MP metabolism. * **Febuxostat Advantage:** It is safer in patients with mild-to-moderate renal impairment compared to allopurinol.

Q: Which of the following drugs causes the least sedation?

Loratadine. **Explanation:** The question tests the classification of antihistamines based on their ability to cross the blood-brain barrier (BBB) and their sedative potential. **1. Why Loratadine is the correct answer:** Loratadine is a **Second-generation H1-antihistamine**. These drugs are characterized by high molecular weight and low lipid solubility, which prevents them from crossing the BBB effectively. Furthermore, they are substrates for the P-glycoprotein efflux pump, which actively removes them from the CNS. Consequently, they lack central sedative effects and are often referred to as "non-sedating antihistamines." **2. Why the other options are incorrect:** * **Hydroxyzine, Promethazine, and Chlorpheniramine** are all **First-generation H1-antihistamines**. * These agents are highly lipid-soluble and easily cross the BBB. * Once in the CNS, they block H1 receptors in the tuberomammillary nucleus (the arousal center), leading to significant sedation. * **Promethazine** and **Hydroxyzine** are particularly potent sedatives, often used clinically for their hypnotic or anti-anxiety properties. **3. High-Yield Clinical Pearls for NEET-PG:** * **Second-generation H1 blockers:** Loratadine, Cetirizine, Fexofenadine, Desloratadine. * **Fexofenadine** is considered the "least sedating" of all, as it has virtually zero CNS penetration. * **Cetirizine** is a second-generation drug but is unique because it can cause mild sedation in a small percentage of patients (it is the most sedating of the non-sedating group). * **First-generation drugs** also possess significant **anti-cholinergic** side effects (dry mouth, urinary retention, blurred vision), which are largely absent in second-generation agents.

Q: Which of the following drugs is NOT used for erectile dysfunction?

Phenylephrine. **Explanation:** The correct answer is **Phenylephrine** because it is a selective **$\alpha_1$-adrenergic agonist**. In the context of penile physiology, sympathetic stimulation (via $\alpha_1$ receptors) causes vasoconstriction of the cavernous arteries and contraction of the trabecular smooth muscle, leading to **detumescence** (loss of erection). Clinically, Phenylephrine is actually the drug of choice for treating **priapism** (a prolonged, painful erection) via intracavernosal injection. **Analysis of Incorrect Options:** * **Vardenafil:** A potent **PDE-5 inhibitor**. It prevents the breakdown of cGMP in the corpus cavernosum, leading to smooth muscle relaxation and increased blood flow. It is a first-line oral treatment for erectile dysfunction (ED). * **Apomorphine:** A **dopamine (D2) receptor agonist** that acts centrally on the hypothalamus to induce an erection. While less commonly used now, a sublingual formulation was developed specifically for ED. * **Yohimbine:** An **$\alpha_2$-adrenergic antagonist**. It works by increasing central sympathetic outflow and blocking peripheral $\alpha_2$ receptors, which theoretically enhances blood flow to the penis. It was historically used for psychogenic ED. **High-Yield Clinical Pearls for NEET-PG:** * **Alprostadil (PGE1):** Another important drug for ED; it increases cAMP and can be administered via intracavernosal injection or intraurethral suppository. * **PDE-5 Inhibitor Contraindication:** Never co-administer with **nitrates**, as this can lead to severe, life-threatening hypotension. * **Sildenafil Side Effect:** Can cause "blue-tinted vision" (cyanopsia) due to cross-inhibition of PDE-6 in the retina.

Q: In the given pharmacodynamic curve, point A corresponds to:

ED50. ***ED50*** - Point A on the **dose-response curve** represents the dose that produces **50% of the maximum response**, which is the definition of **ED50**. - It is located at the **intersection** of the 50% response level with the curve, read directly from the **x-axis (dose axis)**. *Potency* - **Potency** refers to the overall **position of the curve** on the x-axis, not a specific point like A. - A more potent drug has its entire curve **shifted to the left**, requiring lower doses for the same effects. *Efficacy* - **Efficacy** represents the **maximum response** achievable by a drug, shown as the **plateau height** of the curve. - Point A is on the **dose axis**, not at the maximum response level, so it cannot represent efficacy. *LD50* - **LD50** is the **lethal dose** for 50% of the population, derived from **quantal dose-response curves**. - This parameter is used for **toxicity studies**, not therapeutic effect measurements shown in graded dose-response curves.

Q: All of the following agents are used in the management of obesity except:

Neuropeptide Y analogues. **Explanation:** The management of obesity involves targeting energy intake, absorption, or expenditure. To understand the correct answer, one must distinguish between **orexigenic** (appetite-stimulating) and **anorexigenic** (appetite-suppressing) pathways. **1. Why Neuropeptide Y (NPY) analogues are the correct answer:** Neuropeptide Y is one of the most potent **orexigenic** peptides found in the hypothalamus. It stimulates food intake and promotes fat storage. Therefore, an **NPY analogue** would increase hunger and lead to weight gain, making it contraindicated for obesity. Conversely, NPY *antagonists* are the agents being researched for obesity management. **2. Analysis of incorrect options:** * **Orlistat:** A potent, reversible inhibitor of gastric and pancreatic lipases. It prevents the hydrolysis of dietary triglycerides into absorbable free fatty acids, reducing fat absorption by approximately 30%. * **Sibutramine:** A combined norepinephrine and serotonin reuptake inhibitor (SNRI). It promotes satiety and increases metabolic rate. (Note: It has been withdrawn in many countries due to cardiovascular risks but remains a classic textbook example). * **Olestra:** A non-absorbable fat substitute (sucrose polyester) used in food preparation. It provides the texture of fat without the calories, as it cannot be hydrolyzed by digestive enzymes. **High-Yield Clinical Pearls for NEET-PG:** * **Liraglutide/Semaglutide:** GLP-1 analogues are currently the "gold standard" medical management for obesity. * **Lorcaserin:** A selective 5-HT2C receptor agonist (anorexiant). * **Qsymia:** A fixed-dose combination of Phentermine and Topiramate. * **Contrave:** A combination of Naltrexone and Bupropion. * **Steatorrhea:** The most common side effect of Orlistat due to malabsorbed fat.

Q: Receptor-mediated action is not seen in which of the following?

Antacids. **Explanation:** The core concept tested here is the **mechanism of drug action**. Most drugs act by binding to specific **receptors** (proteins), but some exert their effects through non-receptor-mediated physical or chemical processes. **Why Antacids are the correct answer:** Antacids (e.g., Aluminum hydroxide, Magnesium hydroxide) act through a **purely chemical neutralization reaction**. They are weak bases that react directly with gastric hydrochloric acid (HCl) to form salt and water, thereby increasing the pH of the gastric contents. This process does not involve binding to any cellular receptor. **Analysis of Incorrect Options:** * **Antipsychotics:** These drugs act primarily by blocking **Dopamine (D2) receptors** in the mesolimbic pathway of the brain. * **Benzodiazepines:** These act as positive allosteric modulators of the **GABA-A receptor** complex, increasing the frequency of chloride channel opening. * **Alcohol (Ethanol):** While alcohol has complex effects, its primary sedative-hypnotic actions are mediated through the enhancement of **GABA-A receptors** and inhibition of NMDA glutamate receptors. **High-Yield Clinical Pearls for NEET-PG:** Other examples of **Non-Receptor Mediated Mechanisms** frequently asked in exams include: 1. **Physical Action:** Adsorbents (Activated Charcoal), Osmotic laxatives (Lactulose, Magnesium sulfate), and Osmotic diuretics (Mannitol). 2. **Chemical Action:** Chelating agents (EDTA, Dimercaprol) which bind to heavy metals. 3. **Counterfeit Incorporation:** Purine/Pyrimidine analogues (Anticancer drugs) that get incorporated into DNA. 4. **Enzyme Inhibition:** Drugs like Neostigmine (AChE) or Captopril (ACE).

Question 1

Which of the following drugs is NOT used in the management of obesity?

Accepted Answer

Neuropeptide Y Agonist

Answer

Orlistat

Answer

Sibutramine

Answer

Olestra

Question 2

Which one of the following is a prodrug?

Accepted Answer

Enalapril

Answer

Dopamine

Answer

Ampicillin

Answer

Prednisolone

Question 3

What is the primary aim of post-marketing studies for drugs?

Accepted Answer

To assess the safety of the drug and compare it with other medicines.

Answer

To evaluate the efficacy of the drug.

Answer

To determine the optimal dosage of the drug.

Answer

To study alterations in drug absorption, distribution, and binding.

Question 4

Which of the following is the exact mechanism of action of Nitric Oxide (NO)?

Accepted Answer

Increase in cyclic guanosine monophosphate (cGMP)

Answer

Increase in cyclic adenosine monophosphate (cAMP)

Answer

Increase in prostaglandin E2 (PGE2)

Answer

Increase in prostaglandin D4 (PGD4)

Question 5

A 40-year-old female with a history of myasthenia gravis on treatment with azathioprine presents with arthritis involving the knee joint and a serum uric acid of 12 mg%. Which of the following is the best drug for lowering uric acid in this patient?

Accepted Answer

febuxostat

Answer

allopurinol

Answer

both allopurinol and febuxostat

Answer

penicillamine

Question 6

Which of the following drugs causes the least sedation?

Accepted Answer

Loratadine

Answer

Hydroxyzine

Answer

Promethazine

Answer

Chlorpheniramine

Question 7

Which of the following drugs is NOT used for erectile dysfunction?

Accepted Answer

Phenylephrine

Answer

Apomorphine

Answer

Yohimbine

Answer

Vardenafil

Question 8

In the given pharmacodynamic curve, point A corresponds to:

Accepted Answer

ED50

Answer

Potency

Answer

Efficacy

Answer

LD50

Question 9

All of the following agents are used in the management of obesity except:

Accepted Answer

Neuropeptide Y analogues

Answer

Orlistat

Answer

Sibutramine

Answer

Olestra

Question 10

Receptor-mediated action is not seen in which of the following?

Accepted Answer

Antacids

Answer

Alcohol

Answer

Antipsychotics

Answer

Benzodiazepines

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?